Reset

Advanced Filters
11:00am - 12:15pm EDT - March 18, 2021

Thursday


Objectives:
  • Identify clinical challenges in managing patients with a variety of cancers.
  • Develop an evidence-based approach for the management of these patients.
Thursday
11:00am - 11:45am EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe current surgical management strategies for testicular germ cell tumors.
  • Assess the benefits and limitations of current surgical techniques.
  • Discuss the supportive care needs that arise during surgical management of testicular germ cell tumors.
Thursday
11:00am - 11:45am EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Discuss the impact cancer and its treatment can have on a survivor’s work status, work performance, and job satisfaction.
  • Review interventions that may enhance return-to-work in cancer survivors.
  • Explain how physical activity and other healthy lifestyle habits may help survivors return to work.
Thursday
11:45am - 12:30pm EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe imaging techniques used in the identification of distant metastases in patients with prostate cancer.
  • Review data supporting the use of PARP inhibitors in patients with metastatic castration-resistant prostate cancer and mutations in certain homologous recombination genes.
  • Integrate updates to NCCN Guidelines® for Prostate Cancer into clinical practice to optimize patient care.
03:30pm - 05:00pm EDT - March 18, 2021

Thursday


Objectives:
  • Discuss the benefits and challenges associated with collecting and utilizing patient-reported outcomes.
  • Apply best practices for incorporating patient-reported outcomes into routine clinical care.
Thursday
03:30pm - 04:15pm EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Select optimal adjuvant treatment strategies for patients with HER2-positive early-stage breast cancer based on risk of recurrence.
  • Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer.
  • Plan effective therapy for patients with HER2-positive metastatic breast cancer and central nervous system (CNS) metastases.
Thursday


Objectives:
  • Identify the most common hereditary RCC syndromes and their clinical features.
  • Discuss screening and surveillance strategies for patients with a confirmed hereditary RCC syndrome.
  • Review treatment options for patients with a confirmed hereditary RCC syndrome.
Thursday
03:30pm - 04:00pm EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Recognize the importance of assessing mutational status in GISTs and its treatment and prognostic implications.
  • Review the existing treatment modalities for unresectable and metastatic GISTs and the high rate of drug resistance.
  • Discuss the impact of avapritinib and ripretinib, the two new FDA-approved agents, on the treatment of advanced GISTs.
Thursday


Objectives:
  • Discuss the role of NGS-based techniques in the management of gastroesophageal cancers.
  • Describe the treatment options for second-line and subsequent therapy for patients with metastatic gastroesophageal cancers.
  • Compare and contrast the current evidence for treating metastatic gastric cancer with targeted therapies, and when appropriate, include in the management of these patients.
Thursday
04:15pm - 05:00pm EDT - March 18, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Select optimal neoadjuvant/adjuvant therapy for locally advanced triple negative breast cancer.
  • Recognize key patient factors that influence selection of systemic therapy for metastatic triple negative breast cancer.
  • Optimally manage common toxicities related to new agents used to treat triple negative breast cancer.
11:00am - 12:30pm EDT - March 19, 2021

Friday


Objectives:
  • Identify clinical challenges in managing patients with a variety of cancers.
  • Develop an evidence-based approach for the management of these patients.
Friday


Objectives:
  • Recognize the barriers to fertility preservation in AYAs with cancer, including lack of adequate knowledge among providers.
  • Assess the risks of gonadotoxicity/gonadal insufficiency associated with various anti-neoplastic regimens, as estimated by the standardized risk stratification model proposed by the Oncofertility Consortium.
  • Discuss the various fertility preservation methods and alternatives currently available for female and male AYAs.
Friday
11:00am - 11:45am EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Evaluate novel and emerging treatment strategies for acute myeloid leukemia (AML) and integrate them into the management of appropriate patients.
  • Compare and contrast factors used for posttreatment risk stratification in AML.
  • Summarize supportive care considerations for novel and emerging AML therapies.
Friday


Objectives:
  • Recognize health-related quality of life issues that impact patients with head and neck cancer.
  • Identify strategies for optimal nutrition management in patients with head and neck cancer.
  • Describe the risk of dental complications following radiation therapy treatment to the head and neck and strategies to prevent and address complications, including use of advanced radiation therapy techniques.
Friday


Objectives:
  • Discuss the results of recent and emerging clinical trials of immune checkpoint inhibitors and their potential impact on treatment of urothelial bladder cancer.
  • Review recent updates to the NCCN Guidelines for Bladder Cancer and how they may be incorporated into clinical practice.
  • Describe systemic therapy options for patients with urothelial bladder cancer, along with how patient and disease characteristics can guide therapy choice.
Friday
11:45am - 12:30pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Select optimal therapies for patients with heavily pretreated multiple myeloma (MM) based on individual patient and disease characteristics.
  • Manage toxicities of the newer agents and combination regimens in patients with MM.
  • Review current management strategies of SMM and MM and effectively convey the benefits and risks of clinical trial participation to patients.